Lercanidipine Bouchara-Recordati (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels in the smooth muscle of arterial walls. By preventing calcium entry, it induces vasodilation, reduces peripheral vascular resistance, and consequently decreases systolic and diastolic blood pressure without markedly affecting heart contractility.

The appropriate dose of lercanidipine is individualized by the prescribing clinician based on the patient’s blood‑pressure profile, comor‑bidities, and concomitant medications. The prescriber determines the strength, frequency, and any titration schedule required for safe and effective therapy.

Safety data for lercanidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lercanidipine, as a dihydropyridine calcium‑channel blocker, primarily induces arterial vasodilation, whereas ACE inhibitors reduce angiotensin‑II formation and beta‑blockers decrease heart rate and contractility. Choice of therapy depends on patient comorbidities, tolerability, and physician preference; lercanidipine is often favored for its once‑daily dosing and favorable metabolic profile.

Lercanidipine tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Keeping the product in a dry, cool place helps maintain its potency throughout the shelf‑life.

Lercanidipine is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed to ensure proper absorption.

Serious adverse events, although rare, include severe hypotension, myocardial infarction, hepatic dysfunction, angioedema, and life‑threatening cardiac arrhythmias. Patients should be instructed to seek immediate medical attention if they experience symptoms such as fainting, chest pain, severe dizziness, or swelling of the face or throat.

Lercanidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation. Caution is advised in individuals with severe hepatic impairment, unstable angina, or those taking strong CYP3A4 inhibitors without appropriate dose adjustment.